Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06987513
PHASE2

RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Sponsor: Altimmune, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly

Official title: RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-05-15

Completion Date

2026-06

Last Updated

2025-11-19

Healthy Volunteers

No

Interventions

DRUG

Pemvidutide

Pemvidutide 2.4mg

OTHER

Placebo

Subcutaneous injection

Locations (12)

Altimmune Clinical Study Site

Los Angeles, California, United States

Altimmune Clinical Study Site

Aurora, Colorado, United States

Altimmune Clinical Study Site

New Haven, Connecticut, United States

Altimmune Clinical Study Site

Fort Myers, Florida, United States

Altimmune Clinical Study Site

University Park, Florida, United States

Altimmune Clinical Study Site

North Canton, Ohio, United States

Altimmune Clinical Study Site

Tulsa, Oklahoma, United States

Altimmune Clinical Study Site

Philadelphia, Pennsylvania, United States

Altimmune Clinical Study Site

Providence, Rhode Island, United States

Altimmune Clinical Study Site

Charleston, South Carolina, United States

Altimmune Clinical Study Site

Charlottesville, Virginia, United States

Altimmune Clinical Study Site

Richmond, Virginia, United States